Annual Report 2007-2008


Hoosier Oncology Group
We dedicate this to all the families and friends who have lost a loved one to cancer this year.

In particular, we wish to acknowledge the passing of our dear friend, Dr. Stephen Williams. The world is minus one more great man, father, husband and scientist.
It has been a distinct honor and privilege to serve as Chairman of the Hoosier Oncology Group. As the HOG enters its 25th year, I’d like to take just a moment to reflect on where we’ve been, where we are, and (most importantly) where we are going.

The HOG was founded in 1984 as a collaborative effort between community-based oncology practices and Indiana University. The model was successful, resulting in the completion of landmark trials, establishing or maintaining standards of practice. The HOG has served the oncology community well, challenging accepted dogma in some instances, charting new territory in other instances. The organization has maintained continuity in the areas of leadership and membership for over two decades.

As the landscape of oncology has changed over the last decade, the HOG has been required to change as well. Unfunded studies with little regulatory oversight are no longer feasible, nor desirable. There has been an explosion in research to understand the biology of cancer and as a result, far more companies have become deeply engaged in the field of oncology drug development. As a result of these and other changes, the HOG has developed the necessary infrastructure to meet the challenges of conducting the relevant research of today.

In 2007, the HOG became a 501(c)3, not-for-profit foundation independent from the Walther Cancer Institute. In November of 2007, I became only the third Chairman of the HOG and in October of 2008, Peter “Quake” Pletcher became only the fourth Executive Director. The Executive Committee of the HOG was disbanded in 2007, and a Board of Directors was created. New by-laws were enacted and restructuring took place to position the organization to meet the challenges of a new decade. While the process of reorganization has been very difficult at times, the HOG is emerging as a more effective cancer research group. New partnerships are being formed, deeper engagement with our academic leaders and clinical trial working groups is taking place, and a new vision for the next decade is under review by the Board of Directors.

I am absolutely confident that the HOG will continue to be a leader in cancer research. The ingredients are there for success: a deep talent pool, desire for success, and a tradition of excellence. The HOG embodies the sentiments of the Chinese proverb, “Those who say it cannot be done should not interrupt the person doing it.” Now, back to work!

Nasser Hanna, M.D.
Chairman, Hoosier Oncology Group
"The very essence of leadership is that you have to have a vision." – Theodore Hesburgh, Former President Emeritus, Notre Dame University

Hoosier Oncology Foundation, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary/Treasurer, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Hoosier Oncology Group, Inc.

Nasser Hanna, M.D., Chairman, Associate Professor of the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Robin Zon, M.D., F.A.C.P., Vice-Chair, Principal Investigator for the Northern Indiana Cancer Research Consortium, South Bend, IN

James Ruckle, Ph.D., Secretary, President and CEO of Walther Cancer Foundation, Indianapolis, IN

Fuad Hammoudeh, Treasurer, Administrator of Cancer Programs at Clarian Health, Indianapolis, IN

Lawrence Einhorn, M.D., Chief Medical Officer, Distinguished Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Members At Large

Prasad Mantravadi, M.D., Principal Investigator for Radiation Oncology Associates, Evansville, IN

Patrick J. Loehrer, M.D., Interim Director and Medical Director at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

Wael Harb, M.D., Principal Investigator of Horizon Oncology Center, Lafayette, IN

Naftali Bechar, M.D., Principal Investigator of Howard Regional Health Systems, Kokomo, IN

Rudolph M. Navari, M.D., Ph.D.
Professor of Medicine, Assistant Dean and Director Indiana University School of Medicine, South Bend Director, Notre Dame Cancer Institute

George W. Sledge, Jr., M.D.
Ballvé-Lantero Professor of Oncology at Indiana University, Indianapolis, Co-Director Indiana University Melvin and Bren Simon Cancer Center's Breast Cancer Program

Patrick J. Loehrer Sr., M.D.
Bruce Kenneth Wiseman Professor of Medicine, Director, Division of Hematology-Oncology, Interim Director, Howard Regional Health Systems, Kokomo, IN
Clinical Trials Working Groups Co-Chairs

**BREAST**  
Kathy Miller, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Robin Zon, M.D., F.A.C.P., Northern Indiana Cancer Research Consortium, South Bend, IN

**CENTRAL NERVOUS SYSTEM**  
Mark Henderson, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Charles Nock, M.D., University Hospital Case Medical Center, Cleveland, OH

**GASTROINTESTINAL**  
Gabi Chiorean, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Mary Mulcahy, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

**GYNECOLOGY**  
Daniela Matei, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Greg Sutton, M.D., St. Vincent Oncology, Indianapolis, IN

**RADIATION**  
Achilles Fakiris, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Rao Prasad Mantravadi, M.D., Ft. Wayne Oncology & Hematology, Fort Wayne, IN

**GENITOURINARY**  
Noah Hahn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Guru Sonpavde, M.D., US Oncology, Texas

**HEMATOLOGY**  
Sheriff Farag, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Tamila Kindwall-Keller, M.D., University of Cleveland, OH

**HEAD & NECK**  
Romnee Clark, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Daniel Weed, M.D., Clarian West Cancer Center, Indianapolis, IN

**SUPPORTIVE CARE**  
Lawrence Einhorn, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Rudi Navari, M.D., University of Notre Dame, South Bend, IN

**THORACIC**  
Nasser Hanna, M.D., Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN  
Jyoti Patel, M.D., Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
**Patients Are Our #1 Focus**

The Hoosier Oncology Group has made patients our #1 focus. We are committed to delivering the best cancer research treatment options to patients within their community.

In 2007, the Hoosier Oncology Group initiated the Patient Advocacy Program to assist in raising public awareness about important cancer issues, such as the need for cancer support services, education, research and legislation.

The Patient Advocacy Program supports enrollment in Hoosier Oncology Group clinical trials by partnering with patient advocates throughout the community utilizing a well-designed program that offers support through newsletters, symposiums, health fairs and support groups within the communities. Linking the Hoosier Oncology Group and the patient advocate community is mutually beneficial for patients and families touched by cancer and will advance the dissemination of information about clinical research.

"The Northern Indiana Cancer Research Consortium has partnered with the Hoosier Oncology Group to develop the Patient Advocacy Program.

Through this collaboration, the advocates have been able to get involved, educate, provide support to other cancer patients’ in the chemotherapy room, and lobby for legislation that will mandate the State of Indiana to provide insurance coverage for clinical trial participants."

Susan Haithcox R.N., B.S.N., C.C.R.P., O.C.N., Research Nurse Manager
“Being a volunteer and research advocate for the Hoosier Oncology Group is my way of giving back.

Thousands and thousands of people have participated in cancer trials. Because of their efforts, we’ve gained more knowledge, tools, and treatments. If people don’t participate then we don’t have a chance.

THE ONLY way to find a cure is through clinical trials.”

Ted Stansbury, Cancer Survivor, 5-year Volunteer and Cancer Research Advocate

With over 50 Hoosier Oncology Group clinical sites across the country, the best cancer treatments are available to you within your own community.
“I have the opportunity, unavailable to me with other cancer research groups, to participate in the process of study design and offer input about the feasibility of a particular trial at the community level and coauthor manuscripts as a result of my patient accrual.”

Bill Fisher, M.D., F.A.C.P., Past Vice Chairman of the Hoosier Oncology Group, Clinical Professor of Medicine at Indiana University, and Co-Director of Cancer Services at Ball Memorial Hospital.

“The Hoosier Oncology Group has been an advocate of community clinical research since its inception. HOG has high standards for their clinical trials and does quality research. They have been a great mentor and friend throughout the years. HOG has benefited the entire state of Indiana in promoting high quality clinical research in the community setting.”

Robin Zon, M.D., Northern Indiana Cancer Research Consortium, Vice Chairman, Investigator and Hoosier Oncology Group Clinical Trial Working Group Co-Chair.
Community Partnerships Are Our Lifeblood

The Hoosier Oncology Group has a large network of community research sites throughout the midwest and across the nation.

We consider our relationship with the community physicians and medical professionals to be the lifeblood of our ability to reach our mission of providing the best cancer treatment options to patients within their own communities.

The Hoosier Oncology Group values all our community partners and we strive to continually build and enrich our network of community research sites through training and collaborative opportunities.

4 out of the 5 top enrolling Hoosier Oncology Group clinical sites in 2007-2008 were our valued community physician sites.

Top 5 Enrolling Sites 2007-2008

- Northern Indiana Cancer Research Consortium, South Bend, IN
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
- Horizon Oncology Center, West Lafayette, IN
- Community Regional Cancer Center, Indianapolis, IN
- Medical Consultants, P.C., Muncie, IN
- All Other
The Hoosier Oncology Group has been an excellent organization for young investigators like me to participate as primary investigators in novel multi-site therapeutic trials in a shorter time frame than traditional national cooperative group settings. This has been instrumental in my early career research success.

Noah Hahn, M.D., Assistant Professor at the Indiana University School of Medicine and oncologist at the Indiana University Melvin and Bren Simon Cancer Center. He has been a HOG investigator for over 3 years and specializes in genitourinary cancers.

Through Collaboration, Discoveries Are Realized

The Hoosier Oncology Group values our community and academic partner’s perspectives on cancer therapies, and we recognize that the physicians and clinical research site professionals are on the frontlines of cancer treatment each day.

From their hands-on experience, they know what therapies are working - or not working - to eliminate cancer as a cause of suffering and death. We base the majority of our study designs on the expertise of our professional partners so that Hoosier Oncology Group research tests the effectiveness of treatments available.

Twice a year, the Hoosier Oncology Group hosts the Clinical Trials Working Group Meeting, which gives the community and academic oncologists a venue to collaborate and grow new concepts and ideas for new cancer studies. It is through these collaborations that many discoveries have been realized.
6 out of 7 studies opened in 2007-2008 were investigator-initiated.

**Hoosier Oncology Group - the “Guardian of Good Research”**

The Hoosier Oncology Group prides itself on our reputation in the clinical research industry as a ‘guardian of good research’. We are true to the data and we report all study outcomes - both positive and negative.

This past year, the Hoosier Oncology Group had 15 publications based on our findings.
Without Promising Pharmaceuticals, Advancing Cancer Treatment Is Not Possible

The Hoosier Oncology Group partners with pharmaceutical companies to deliver promising drug therapies to cancer patients. It is through these collaborations that the efficacy of pharmaceutical drug combinations are determined.

Through strategic relationships with select pharmaceutical partners, the Hoosier Oncology Group aligns great science and unmet medical needs with pharmaceutical industry’s need for quality data and speedy accrual to support important investment decisions in phase II portfolios.

“As someone who is always looking for qualified and productive clinical trial sites, I have truly enjoyed working with the Hoosier Oncology Group.

I am confident that any study they choose to activate will receive the attention necessary to make it successful.

The [Hoosier Oncology Group] clinical study staff are a pleasure to work with.

I have considered them valuable partners in every project on which we have collaborated.”

- Senior Medical Liaison with a leading pharmaceutical company, Hoosier Oncology Group industry partner for over 6 years.
Noted Research Outcomes in 2007-2008

At the annual American Society of Clinical Oncology Meeting in May 2008, several Hoosier Oncology Group studies were recognized for our outstanding contributions to cancer research.

POSTER DISCUSSION
"A Phase III Trial of cisplatin (P) plus Etoposide (E) plus Concurrent Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients (pts) with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): HOG LUN01-24” was presented as a poster discussion.
OUTCOME: Lida Mina, M.D., an Indiana University Fellow, and her research team confirmed the previous findings that consolidation docetaxel does not improve survival following the treatment regimen of cisplatin + etoposide + radiation, is associated with significant toxicities, and can no longer be considered as standard treatment for patients with inoperable stage III non-small-cell lung cancer.

ORAL PRESENTATION
"A Phase II Study of Oral Enzastaurin in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane-Containing Regimen: HOG BRE05-97” received the second highest form of recognition and was presented as an oral presentation.
OUTCOME: Ian Krop, M.D., an oncologist from Dana Farber Cancer Institute, in collaboration with multiple centers from around the country, including researchers from the Indiana University Melvin and Bren Simon Cancer Center and the Northern Indiana Cancer Research Consortium, concluded that enzastaurin monotherapy was well tolerated, but had no activity in a pretreated population of patients with metastatic breast cancer. Based on preclinical data, phase II studies are ongoing to evaluate the combination of enzastaurin with chemotherapy or hormone therapy.

ABSTRACT PUBLICATION
"A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: HOG GU03-67”.
OUTCOME: Noah Hahn, M.D., Assistant Professor at the Indiana University School of Medicine and oncologist with the Indiana University Melvin and Bren Simon Cancer Center, and his research team concluded that this study demonstrated that pemetrexed has modest activity in the second line treatment of metastatic castrate resistant prostate cancer patients who progressed on prior docetaxel therapy. However, this activity is not sufficient to recommend further testing in a phase III trial.
Hoosier Oncology Group, Inc.

Statement of Cashflow from Operating Activities
June 30, 2008

Change in net assets $ 3,792,252

Adjustments to reconcile change in net assets to net cash used from operating activities:

Depreciation 76,072
Contribution of assets (216,913)
Change in assets and liabilities:
Accounts receivable (1,015,850)
Contributions and grants receivable (2,217,251)
Prepaid expenses (74,513)
Accounts payable 341,365
Affiliate sites payable 621,531
Accrued payroll 39,818
Deferred revenue 285,118

Net change in cash and cash equivalents 1,631,629

Cash and cash equivalents at beginning of year -

Cash and cash equivalents at end of year $ 1,631,629

Supplementary disclosure

Contributions of assets, net of Liabilities from Walther Cancer Foundation $ 1,353,795
## Hoosier Oncology Group, Inc.

### Statement of Activities

**June 30, 2008**

<table>
<thead>
<tr>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REVENUES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions and grant support</td>
<td>$ 3,888,856</td>
<td>$ 122,500</td>
</tr>
<tr>
<td>External support - research</td>
<td>3,049,114</td>
<td>-</td>
</tr>
<tr>
<td>Federal research grants</td>
<td>597,317</td>
<td>-</td>
</tr>
<tr>
<td>Interest income</td>
<td>43,067</td>
<td>-</td>
</tr>
<tr>
<td>Other income</td>
<td>45,695</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total revenues</strong></td>
<td>7,624,049</td>
<td>122,500</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator initiated research</td>
<td>1,358,375</td>
<td>-</td>
</tr>
<tr>
<td>Industry research</td>
<td>766,731</td>
<td>-</td>
</tr>
<tr>
<td>Government research</td>
<td>670,360</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>2,795,466</td>
<td>-</td>
</tr>
<tr>
<td>Supporting services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration</td>
<td>1,052,638</td>
<td>-</td>
</tr>
<tr>
<td>Fundraising</td>
<td>106,193</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>1,158,831</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>3,954,297</td>
<td>-</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>3,669,752</td>
<td>122,500</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$ 3,669,752</td>
<td>$ 122,500</td>
</tr>
</tbody>
</table>
### Hoosier Oncology Group, Inc.

**Statement of Financial Position**  
**June 30, 2008**

#### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,631,629</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>1,015,850</td>
</tr>
<tr>
<td>Grants and contributions receivable</td>
<td>2,217,251</td>
</tr>
<tr>
<td>Prepaid expense</td>
<td>74,513</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>140,841</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$5,080,084</strong></td>
</tr>
</tbody>
</table>

#### LIABILITIES AND NET ASSETS

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable</td>
<td>$341,365</td>
</tr>
<tr>
<td>Affiliate sites payable</td>
<td>621,531</td>
</tr>
<tr>
<td>Accrued payroll</td>
<td>39,818</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>285,118</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>1,287,832</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>3,669,752</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>122,500</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>3,792,252</strong></td>
</tr>
</tbody>
</table>

**Total liabilities and net assets**               **$5,080,084**
**Thank You to Our Supporters**

The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing cutting-edge research to people within their community.

We are so fortunate to have many friends and supporters who give of their time, money, services, expertise and other valuable resources to help us fulfill our mission.

It is our hope that through their continued generosity, and through the generosity of others, that future generations may not know the pain of cancer.

Our Contributors*

**PLATINUM ($5000 and above)**
- Michiana Hematology Oncology
- Union Hospital

**GOLD ($2500 - $4999)**
- Clarian Health
- Crowe Chizek
- Paragon General Contractors
- The Care Group

**SILVER ($800 - $2499)**
- Cardinal Health Systems
- Cummins, Inc.
- Heroes Foundation
- Home Federal Bank
- Laborers Local 120
- McGowan Insurance Group
- Medical Consultants PC
- Palmer Family Fund
- Mr. Ted Stansbury

**BRONZE ($250-$799)**
- Mr. Greg Bires
- Fifth Third Bank
- Mr. Vince Saul
- City of Columbus
- Coriden Law Office
- Hunt Construction Group
- John McClean, M.D.
- Kathy Miller, M.D.
- Keller Niemann, Inc.
- PA Labs
- Par-Kan Company
- Phil Watts, M.D.

**FRIENDS ($249 and under)**
- B. Agrawal
- L. Akard
- B. Blanton
- Gabi Chiorean, M.D.
- C. Einhorn
- Rafat Mantravadi, M.D.
- Daniel Rushing, M.D.

*The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel and, most importantly, the patients who make our research possible.

Thank you to Deb Cole for creating this report.

*The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2007-June 30, 2008. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask for Cyndi Burkhardt. Thank you for your support!
Our Community Reach Is Far and Wide

Our partnerships with the many academic and community cancer clinics across the United States enables oncologists to participate in meaningful cancer research while providing cutting-edge treatment to patients in their own communities.

Arkansas
Highlands Oncology Group - Fayetteville

Delaware
Christiana Care Health Services - Newark

Illinois
Northwestern University – Chicago
Rush University Medical Center - Chicago
University of Chicago - Chicago
Medical & Surgical Specialists – Galesburg
Ingalls Memorial Hospital - Harvey

Indiana
Cancer Care Center of S. Indiana - Bloomington
Fort Wayne Onc. & Hem., Inc – Fort Wayne
Parkview Research Center – Fort Wayne
Center for Cancer Care at Goshen Hospital - Goshen
Community Regional Cancer Center - Indianapolis
Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
Mary Lou Mayer, M.D. - Indianapolis
Methodist Community Group Oncology Program - Indianapolis
St. Vincent Gynecological Oncology - Indianapolis
Arnett Cancer Care - Lafayette
Horizon Oncology Center - Lafayette
Medical Consultants, P.C. - Muncie
Community Cancer Research - Munster
Cancer Care Center, Inc. – New Albany
Oncology Hematology Associates of Southwest Indiana - Newburgh
Northern Indiana Cancer Research Consortium – South Bend
South Bend Clinic – South Bend
Providence Medical Group – Terre Haute
Good Samaritan Hospital - Vincennes

Massachusetts
Dana Farber Cancer Institute – Boston

Maryland
University of Maryland Greenbaum Cancer Center – Baltimore

Missouri
Siteman Cancer Center – St. Louis

Currently, only 5% of cancer patients participate in clinical trials.
The Hoosier Oncology Group strives to increase the number of cancer patients participating in clinical research.
Nebraska
Nebraska Methodist Hospital and Cancer Center - Omaha
University of Nebraska Medical Center - Omaha

New Jersey
Community Medical Center (FCCC) – Tom’s River
Hunterdon Regional Cancer Center (FCCC) - Flemington
Hem Onc Associates of S.J., P.A. – Mt. Holly
Southern Oncology and Hematology Associates (FCCC) - Vineland

New York
Schwartz Gynecologic Oncology, P.L.L.C. - Brightwaters

Ohio
Oncology Hematology Care, Inc. - Cincinnati
Oncology Partners Network - Cincinnati
University Hospitals of Cleveland - Cleveland

Oregon
OHSU Center for Health and Healing - Portland
Providence Portland Medical Center - Portland

Pennsylvania
Fox Chase Cancer Center – Philadelphia
Pennsylvania Oncology Hematology Associates – Philadelphia
University of Pennsylvania - Philadelphia
Bux-Mont Oncology Hematology Associates (FCCC) – Sellersville

South Carolina
Palmetto Hematology Oncology P.C. – Spartanburg
Medical University of South Carolina - Charleston

Texas
Texas Oncology, P.A. - Dallas
UT Southwestern Medical Center - Dallas
Baylor College of Medicine - Houston

Peru - Lima
Instituto de Enfermedades Neoplasticas (INEN)